Key result
Initiation of an oral loop diuretic at discharge was associated with a lower risk of 30-day HF re-hospitalization or mortality compared with no dose change.
Why the study?
Does loop diuretic dose adjustment at discharge reduce 30-day HF re-hospitalization or all-cause mortality in patients hospitalized with heart failure?
Observational (n=6,119)
Yes
Does loop diuretic dose adjustment at discharge reduce 30-day HF re-hospitalization or all-cause mortality in patients hospitalized with heart failure?
Initiating loop diuretics at discharge for diuretic-naive patients hospitalized with HF is associated with improved 30-day outcomes, but adjusting doses for those already on chronic therapy is not.
Answers are grounded in this paper and cite their sources.
Should not yet change practice; leaves open benefit of initiation in diuretic-naive patients pending RCTs.
AIMS: Loop diuretics are a cornerstone of heart failure (HF) treatment, but data regarding diuretic dose adjustments after a HF hospitalization and the association with subsequent outcomes are limited. This study was therefore conducted to determine these factors. METHODS AND RESULTS: We analysed data from 6119 patients enrolled in ASCEND-HF, examining the association between loop diuretic use at the time of discharge, compared with admission, and the composite outcome of 30-day HF re-hospitalization or all-cause mortality. The majority of patients, 3921 (64%), were taking a loop diuretic on admission. At discharge, 3411 (56%) patients were prescribed higher doses compared with admission, including 1867 (31%) initiating daily outpatient diuretics; 1912 (31%) had no dose change and 795 (13%) were prescribed lower doses compared with admission. Initiation of an oral loop diuretic at discharge was independently associated with better 30-day outcomes compared with no dose change [adjusted odds ratio (OR) 0.51, 95% confidence interval (CI) 0.37-0.68]. However, for patients that were already established on a loop diuretic prior to admission, change in the dose at discharge was not associated with improved outcomes compared with no dose change (adjusted OR 0.92, 95% CI 0.79-1.07). CONCLUSIONS: In a large multinational clinical trial, 56% of patients hospitalized with HF were either initiated on a daily loop diuretic at discharge or discharged on higher doses compared with admission. In patients established on diuretics prior to hospitalization, we found no association between changes to chronic doses at discharge and improved outcomes, whereas initiation of loop diuretic therapy was associated with better outcomes compared with no dose change.
No takes yet. Share an insight, caveat, or question.
DeVore et al. (2015) conducted an observational in Heart failure (n=6,119). Loop diuretic initiation at discharge vs. No dose change compared with admission was evaluated on Composite outcome of 30-day HF re-hospitalization or all-cause mortality (OR 0.51, 95% CI 0.37-0.68). Initiation of an oral loop diuretic at discharge was associated with a lower risk of 30-day HF re-hospitalization or mortality compared with no dose change.
Synapse has enriched 10 related papers. Consider them for comparative context: